Cost-effectiveness of newer treatment strategies for influenza.
about
Cost-effective approaches to influenza prevention and treatment.Economic value of seasonal and pandemic influenza vaccination during pregnancy.Antiviral medications for pregnant women for pandemic and seasonal influenza: an economic computer model.Recommendations for the prevention and treatment of influenza using antiviral drugs based on cost-effectiveness.To test or to treat? An analysis of influenza testing and antiviral treatment strategies using economic computer modeling.Understanding the socioeconomic heterogeneity in healthcare in US counties: the effect of population density, education and poverty on H1N1 pandemic mortality.Do pediatricians manage influenza differently than internists?Targeted vs. systematic early antiviral treatment against A(H1N1)v influenza with neuraminidase inhibitors in patients with influenza-like symptoms: clinical and economic impactThe potential economic value of a Staphylococcus aureus vaccine for neonatesThe impact of economic evaluation on quality management in spine surgery.A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult (age 65 and over) population.Cost-effectiveness of programs to eliminate disparities in elderly vaccination rates in the United States.Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong.From the patient perspective: the economic value of seasonal and H1N1 influenza vaccination.Management of influenza symptoms in healthy adults.Cost-effectiveness of adjuvanted versus nonadjuvanted influenza vaccine in adult hemodialysis patientsEvaluation of a new, rapid, simple test for the detection of influenza virus.The potential economic value of a 'universal' (multi-year) influenza vaccineEconomic evaluations of neuraminidase inhibitors to control influenza.Universal methicillin-resistant Staphylococcus aureus (MRSA) surveillance for adults at hospital admission: an economic model and analysis.An economic model assessing the value of microneedle patch delivery of the seasonal influenza vaccine.Epidemiological study of influenza virus infections in young adult outpatients from Buenos Aires, Argentina.Quantifying the economic value and quality of life impact of earlier influenza vaccination.Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland.Use of rapid tests and antiviral medications for influenza among primary care providers in the United StatesEconomics of influenza vaccine administration timing for children.The timing of influenza vaccination for older adults (65 years and older).Appropriateness of antiviral prescribing for influenza in primary care: a retrospective analysis.Effects of local variation, specialty, and beliefs on antiviral prescribing for influenza.Bayesian Classification and Regression Trees
P2860
Q30233084-7F920931-2892-4FA5-AADF-09160AE6C826Q30382520-23D8DD61-7B90-45C9-93DD-C8AFAF2DBBDAQ30385821-577870D2-36AE-4228-A08A-958A710B4734Q30390080-B9F687F9-9C42-4132-8699-0B069F0C9874Q30390834-A2CEAFA4-9145-4AD5-AB7A-5D604719C86BQ30405879-0521D51A-7F3A-432B-AE03-C6B846534973Q33330757-1AB8AF53-E1CA-4387-A31B-C5AD08101AA1Q33520449-DE87D70C-3B9A-47F3-92C6-82FBE6A28D64Q33958347-40270EBA-DADB-4DA6-A163-9624F680ACF4Q33971662-6DE1E439-C4C6-40A2-B183-322AF1E3FE1BQ34198807-D646D505-261C-40EF-B944-D2E5EA688D75Q34468509-E907B070-DABC-42DF-B51C-D20DF902D406Q34582189-7026CF0B-A536-4B59-BE2A-8C69801FF373Q34613417-6F2456B6-4F7E-40D1-8BF6-4C8E0813793EQ34742405-3B65B3AA-4E09-4D4B-9DF2-ACBB07D0F2B5Q34903425-9D30AC55-9C2B-4C34-814E-CB12178FF923Q35205172-4E075029-09FD-4561-AA5E-90A98FE5FFBDQ35661358-E2B14A19-0357-419B-8D05-1EB30599DA7FQ36020202-24169085-E968-46C2-9AEE-3EBB8CB99CCEQ36066000-CE22F4DC-C8F8-4D31-8E70-C01232CBAC27Q36215695-E29B5A06-A931-4544-81F7-AA9C0D04CEC9Q36251484-5DDFAC5F-FD74-4640-90DB-1F919AF2AC87Q36403075-9D423456-5B48-4812-96AC-55BB92EA33BFQ36864896-CF87FCDB-3A47-461E-88A9-D519210E65C1Q37087704-BC21DAEF-6E59-40BA-8A2B-CC0824C59047Q37147657-1199A097-88EA-433E-B104-373E3618719CQ37437954-DD085001-C4BE-4B56-A873-5510CF678985Q40476247-56E5C060-D369-4A90-8A6D-4538CF410713Q47236608-C87CB0D6-71CD-48A0-8EB3-D9CC7A269343Q56994275-CA8694F6-9039-41F2-A478-2467CB247372
P2860
Cost-effectiveness of newer treatment strategies for influenza.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Cost-effectiveness of newer treatment strategies for influenza.
@ast
Cost-effectiveness of newer treatment strategies for influenza.
@en
type
label
Cost-effectiveness of newer treatment strategies for influenza.
@ast
Cost-effectiveness of newer treatment strategies for influenza.
@en
prefLabel
Cost-effectiveness of newer treatment strategies for influenza.
@ast
Cost-effectiveness of newer treatment strategies for influenza.
@en
P1476
Cost-effectiveness of newer treatment strategies for influenza.
@en
P2093
Mark S Roberts
P304
P356
10.1016/S0002-9343(02)01222-6
P407
P577
2002-09-01T00:00:00Z